Pulmonx

Pulmonx Corporation is a commercial-stage medical device company that has developed the Zephyr valve, offering minimally invasive treatment for patients with severe emphysema (a type of chronic obstructive pulmonary disease). The company was named one of the 16 most promising private medical technology companies in 2019. Pulmonx is dedicated to developing and marketing minimally invasive medical devices and technologies for diagnosing and treating lung diseases.Pulmonx's solution for treating patients with severe emphysema consists of the Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, and StratX Lung Analysis Platform. This is the first FDA-approved minimally invasive treatment option for severe emphysema.The Zephyr valve procedure is performed via a simple bronchoscopy without incisions or tissue removal, and clinical evidence shows it improves patients' breathing, exercise capacity, and quality of life without subjecting them to the risks of major surgery.The company’s Zephyr® Endobronchial Valve (EBV) treatment* involves placing small one-way valves in the lungs to prevent air from entering the most diseased areas while allowing fluid and trapped air to escape. The goal is to reduce the volume of the diseased portions of the lungs, enabling increased ventilation to healthier lung regions.After receiving "Breakthrough Device" designation from the FDA, Pulmonx obtained FDA premarket approval in June 2018 to commercialize the Zephyr valve. Currently, the Zephyr valve is available in over 25 countries and regions worldwide, with more than 76,000 valves used to treat over 19,000 patients.The company holds the CE Mark for the Zephyr Endobronchial Valves and has submitted a CE Mark application for the Chartis system. The company also has 510(k) marketing clearance in the U.S. for the Chartis system.